Abstract

Vaccinating the brain The epidermal growth factor receptor variant III (EGFRvIII) is often expressed on glioblastoma multiforme (GBM) tumour cells (as well as other tumour types) but not normal cells, which — according to Sampson and colleagues — makes EGFRvIII a potential immunotherapy target for patients with GBM. Sampson and colleagues report a phase II clinical trial of intradermal vaccination with an EGFRvIII-specific peptide (CDX-110) simultaneously with standard or continuous temozolomide (TMZ) in 21 patients with newly diagnosed EGFRvIII+ GBM.